Orchard Therapeutics Plc ADR Up 12.77% To $0.53 After Earnings Beat

Monday, March 6, 2023 - Orchard Therapeutics Plc ADR (ORTX) reported upside earnings and revenues today.

Wall Street earnings per share (EPS) projections for Orchard Therapeutics Plc ADR were at a loss of $0.21 per share. The company beat those estimates with an EPS loss of $0.06 per share. The loss of $0.06 per share (which represents a -71% EPS surprise) led to the company's profits rising 79% compared to last year when the firm reported an EPS loss of $0.29 per share. The increase in Orchard Therapeutics Plc ADR's annual growth rate represents how the business is performing well amid recent economic conditions.

Revenues were upbeat at $7 million. That is an increase of 1346.38% in revenues from the year-ago report and is 31.56% higher than consensus estimates set at $5.3 million.

The stock is up 12.77% to $0.53 after the report.

Despite revenues increasing, earnings decreased, signaling a decline in profit margins.

The average recommendation from Wall Street analysts was a Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Orchard Therapeutics Plc ADR has performed a little below average during the past few months. Before the report, Orchard Therapeutics Plc ADR received a Long-Term Technical Rank by InvestorsObserver of 33, putting it in the bottom half of stocks. The firm was recently trading at a 52-week low of $0.36 on December 28, 2022 and set a 52-week high on March 22, 2022 at $0.89.

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.